Key result
Low-dose continuous infusion of landiolol during cardiac surgery did not significantly reduce the incidence of postoperative supraventricular tachyarrythmia compared to control (32% vs 47%; P=0.50).
Why the study?
The safety and efficacy of low-dose continuous infusion of landiolol in cardiac surgery patients were not well established.
Does low-dose continuous infusion of landiolol safely decrease heart rate and prevent postoperative supraventricular tachyarrythmia in patients undergoing cardiac surgery?
Cohort (n=38)
Does low-dose continuous infusion of landiolol safely decrease heart rate and prevent postoperative supraventricular tachyarrythmia in patients undergoing cardiac surgery?
Absolute Event Rate: 32% vs 47%
p-value: p=0.50
Low-dose continuous infusion of landiolol safely decreases heart rate without hemodynamic deterioration in cardiac surgery patients, though it did not significantly reduce postoperative supraventricular tachyarrhythmias.
Does not support routine low-dose landiolol for postoperative SVT prevention; hypothesis-generating and requires confirmation in randomized trials.
Introduction: Landiolol hydrochloride is an ultra‐short‐acting β‐blocker that is administered intravenously and has many advantages in cardiac surgery. This study was performed to examine the safety and efficacy of low‐dose landiolol continuous infusion in cardiac surgery. Methods and Results: Nineteen patients who underwent either aortic valve replacement or coronary artery bypass surgery received low‐dose continuous infusion of landiolol (2.8 ± 0.75 μg/kg/min. from the time of skin incision until the second postoperative day. Nineteen patients who did not receive landiolol served as controls. Heart rate, arterial pressure, cardiac index, and stroke volume were measured and the occurrence of supraventricular tachyarrythmia was monitored for one week after surgery. Landiolol decreased the heart rate without causing hemodynamic deterioration. The incidence of supraventricular tachyarrythmia was 32% and 47% in the landiolol and control groups, respectively (P = 0.50). Conclusions: Landiolol is effective for decreasing heart rate while maintaining other hemodynamic parameters. Our data did not show a clear prophylactic effect of landiolol on postoperative supraventricular tachyarrythmia.
No takes yet. Share an insight, caveat, or question.
Sato et al. (2011) conducted a cohort in Cardiac surgery (n=38). Landiolol vs. No landiolol was evaluated on Incidence of supraventricular tachyarrythmia (p=0.50). Low-dose continuous infusion of landiolol during cardiac surgery did not significantly reduce the incidence of postoperative supraventricular tachyarrythmia compared to control (32% vs 47%; P=0.50).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: